GalonJerome INSERMFrance

Dr. Jérôme Galon is Director of Research Exceptional class at INSERM (French NIH), and Head of the laboratory of Integrative Cancer Immunology, in Paris, France. Dr. Galon was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France). He holds a Ph.D. degree in Immunology (Jussieu University, Paris, France, 1996). Between 1997 and 2001 he worked at the NIH (National Institute of Health, Bethesda, USA). Since his full-tenured position at INSERM in 2001, he directs interdisciplinary research programs on tumor-Immunology. He is associate Director and co-founder of European Academy of Tumor Immunology (EATI), was board Director of the Society for Immunotherapy of Cancer (SITC). His work on the comprehensive analysis of the tumor-microenvironment and the role of T-cells in human cancer led to the demonstration of the importance of adaptive pre-existing immunity in human cancer, and the concept of cancer immune-contexture. He pioneered the Immunoscore. He was the co-founder and CSO of HalioDx, a Veracyte company, and was SVP and Executive Scientific Director at Veracyte. His contributions have been recognized with numerous awards, including the William B. Coley Award, an international prize which honors the best scientists in the fundamental and cancer immunology, and Award from the National Academy of Science, Award from the National Academy of Medicine. He won the prestigious European Inventor Award in Research category in 2019, the Jeantet-Collen Prize (Switzerland) in 2021, the Galien Prize 2021, and the Duquesne Prize in 2022. He is recognized in the top 1% of the most influential and cited scientist across disciplines.